(CSTL)
NGM – Real Time Price. Currency in USD
23.53
-1.17 (-4.74%)
At close: Mar 27, 2026, 4:00 PM EDT
23.17
-0.36 (-1.53%)
After-hours: Mar 27, 2026, 6:46 PM EDT
Get all premium features to the best stock analysis tool
NGM – Real Time Price. Currency in USD
23.53
-1.17 (-4.74%)
At close: Mar 27, 2026, 4:00 PM EDT
23.17
-0.36 (-1.53%)
After-hours: Mar 27, 2026, 6:46 PM EDT
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
| Name | Position |
|---|---|
| Dr. Jay Braxton Pharm.D. | VP of Marketing & Brand Manager of Uveal Melanoma (UM) |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical |
| Mr. Derek J. Maetzold | Founder, CEO, President & Director |
| Mr. Frank Stokes | CFO & Treasurer |
| Mr. Kevin Doman | Vice President of Sales |
| Mr. Tobin W. Juvenal | Chief Commercial Officer |
| Ms. Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-01-13 | 8-K | cstl-20260111.htm |
| 2025-11-03 | 10-Q | cstl-20250930.htm |
| 2025-08-08 | 8-K | cstl-20250805.htm |
| 2025-08-04 | 10-Q | cstl-20250630.htm |
| 2025-05-23 | 8-K | cstl-20250522.htm |
| 2025-05-05 | 8-K | cstl-20250505.htm |
| 2025-04-09 | DEF 14A | cstl-20250407.htm |
| 2025-03-28 | PRE 14A | cstl-20250328.htm |
| 2025-02-27 | 8-K | cstl-20250227.htm |
| 2025-01-13 | 8-K | cstl-20250112.htm |
| Ms. Keli Greenberg |
| Vice President of Human Resources |
| Ms. Kristen M. Oelschlager R.N. | Chief Operating Officer |
| Ms. Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations |